Constipation Drug Shows Promise in Slowing Kidney Disease in Early Clinical Trial

(DailyAnswer.org) – A drug Americans take for constipation may hold the key to slowing kidney disease progression, challenging decades of expensive treatments that haven’t addressed the root cause of declining kidney function.

Story Snapshot

Japanese researchers found lubiprostone, a common constipation drug, preserved kidney function in 150 chronic kidney disease patients over 24 weeks
The drug works through gut microbiome remodeling and mitochondrial repair rather than just reducing toxins, representing a fundamentally different approach
Lubiprostone costs roughly $5 per dose compared to $10,000+ annually for conventional CKD treatments, potentially saving billions in healthcare costs
The phase 2 trial showed dose-dependent kidney protection without significant safety concerns, prompting calls for larger confirmatory studies

Repurposing a Decades-Old Solution

Lubiprostone, marketed as Amitiza since its 2006 FDA approval for chronic constipation, demonstrated unexpected kidney-protective effects in the LUBI-CKD trial published in Science Advances. Researchers at Tohoku University enrolled 150 Japanese patients with stage IIIb-IV chronic kidney disease across nine medical centers. Patients received either placebo, 8 micrograms, or 16 micrograms of lubiprostone daily for 24 weeks. The trial’s design addressed a critical gap: constipation affects up to 50 percent of advanced CKD patients, yet no randomized trials had examined whether treating it could preserve kidney function.

Mechanism Challenges Medical Orthodoxy

The drug suppressed estimated glomerular filtration rate decline in a dose-dependent manner, but not through the expected pathway. Lead researcher Professor Takaaki Abe discovered lubiprostone remodeled gut bacteria composition, increasing agmatine deiminase activity and polyamine levels like spermidine. These changes improved mitochondrial function in kidney cells. Notably, the drug did not significantly reduce uremic toxins indoxyl sulfate or p-cresyl sulfate, which conventional wisdom held responsible for CKD progression. This finding suggests the medical establishment has focused on the wrong targets for years while patients continued declining toward dialysis dependency.

Economic Impact for Struggling Americans

Chronic kidney disease affects approximately 500 million people globally, with the condition’s management dominating a healthcare market exceeding $50 billion annually by 2025. Current CKD therapies primarily prepare patients for dialysis rather than preventing disease progression. Lubiprostone’s repurposing offers a stark contrast: a generic medication at roughly $5 per dose versus specialized CKD drugs costing over $10,000 yearly. For Americans already squeezed by inflation and rising medical costs, this price difference could mean the choice between affording treatment or facing bankruptcy. The drug’s safety profile in the trial, with no significant dehydration risks despite initial concerns, strengthens its viability for widespread use.

Questions About Regulatory Priorities

As of early 2026, no phase 3 trial announcements have emerged despite the promising results published in December 2025. The delay raises questions about pharmaceutical industry priorities when an inexpensive repurposed drug threatens lucrative existing treatment paradigms. Drug repurposing through FDA’s 505(b)(2) pathway could accelerate approval, yet the process requires funding that benefits generic manufacturers less than patent-protected innovations. Nephrologists have acknowledged the trial’s safety and the microbiome’s role in kidney health, but the research involved only Japanese patients. Broader trials including diverse populations and diabetic patients are needed, yet the financial incentives for such studies remain unclear when profit margins pale compared to proprietary medications.

The trial’s design and execution meet rigorous scientific standards, with peer-reviewed publication in Science Advances confirming its credibility. However, the failure to reduce uremic toxins as a primary endpoint, while still achieving kidney protection, reveals how established medical assumptions may have misdirected research for years. Americans facing CKD have been subjected to treatments targeting symptoms rather than underlying gut-kidney axis dysfunction. The lubiprostone findings suggest a paradigm shift toward gut-targeted therapies could complement existing medications like SGLT2 inhibitors and ACE inhibitors, potentially delaying or preventing the 500,000 Americans currently on dialysis from reaching that desperate stage.